S L E is a chronic multisystem autoimmune disease in which cardiovascular disease is a leading cause of mortality, with a ...

Q4 2024 Management View CEO Jon Congleton highlighted the company's focus on advancing its pivotal trials for lorundrostat, targeting dysregulated aldosterone in patients with uncontrolled and ...

Anticipate topline data from pivotal Advance-HTN trial in March 2025 and pivotal Phase 3 Launch-HTN trial in mid first half of 2025 –– ...

Hypertension (HTN) increases the risk of development of HF and it precedes it in 75% of cases. HF patients are nearly evenly divided between those with reduced left ventricular (LV) function or ...

Mineralys Therapeutics, Inc. (NASDAQ:MLYS) is working on Lorundrostat, which is an aldosterone synthase inhibitor for hypertension [HTN] and other cardio-renal-metabolic conditions. The ...

E-Star BioTech, LLC (“E-Star” or the “Company”), an innovative developer of novel peptides designed to treat cardiovascular, ...

Patients with axSpA and early-stage hypertension face elevated risks for CVEs, likely due to their high inflammatory burden.

SCRATCH-HTN aims to explore a new way of managing high blood pressure (BP), specifically in people who have raised BP despite being on antihypertensive medications. Participants will use an external ...